Revolution Medicines continued to build momentum for its RAS-targeting approach in pancreatic cancer at the American Association for Cancer Research meeting. The company shared updated Phase I/II data on daraxonrasib in first-line metastatic pancreatic ductal adenocarcinoma, including monotherapy and combination-with-chemotherapy cohorts. The updates followed earlier Phase 3 results in previously treated patients that showed a survival benefit versus chemotherapy, fueling investor and clinician interest in broader applicability beyond a narrow biomarker group. Revolution also indicated a phase III RASolute 303 program has started enrolling first-line patients regardless of tumor RAS genotype, aiming to test the strategy in a broader population.